March 3, 2011 — Long-acting, injectable risperidone, the first second-generation antipsychotic available in the United States in this formulation, is no better than oral antipsychotics for the ...
BRIDGEWATER, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announced the U.S. Food and Drug Administration (FDA) approval of risperidone ...
TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the publication of efficacy ...
Purpose: The pharmacology, pharmaceutics, clinical efficacy, adverse effects, cost, and dosage and administration of long-acting risperidone injection are reviewed. Summary: Risperidone is the first ...
TITUSVILLE, N.J., Oct. 9 /PRNewswire-FirstCall/ -- Patients with schizophrenia now have a new administration option for RISPERDAL(R) CONSTA(R) ([risperidone] Long ...
The FDA has approved the injection of Risperdal Consta (risperidone long-acting injection, from Janssen) into the deltoid muscle of the arm for the treatment of schizophrenia. This approval was based ...
Amneal has received the Food and Drug Administration’s approval of risperidone extended-release injectable suspension 12.5 mg/vial, 25 mg/vial, 37.5 mg/vial and 50 mg/vial, which is the generic of ...
MUMBAI, India and NAPLES, Fla., Nov. 14, 2025 /PRNewswire/ -- Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced the launch of ...
Please provide your email address to receive an email when new articles are posted on . Teva Pharmaceuticals and MedinCell announced FDA acceptance of a new drug application for risperidone ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results